Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer

Prior treatment

• Participants with non-healing wound, active ulcer, or bone fracture (not applicable if not receiving bevacizumab)
• Participants with evidence of active or ongoing bowel obstruction (not applicable if not receiving bevacizumab)
• Participants with prior exposure to any FRα-targeted therapy, including MIRV, or any TOP1i Antibody-drug Conjugate (ADC)

Other illness

• Participants with history of (non-infectious) ILD/pneumonitis that required steroids, or supplemental oxygen, or has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at Screening

Other

• Participants with tumours of non-epithelial origin, borderline tumours, clear cell OC, mucinous OC, carcinosarcoma, or low-grade epithelial tumours.

• Participants with confirmed histology of high-grade epithelial serous or endometrioid ovarian, fallopian tube, or primary peritoneal cancer.
• Provision of an archival FFPE tumour sample
• Participants who received at least one, and no more than 2 lines of prior systemic anticancer therapy.
• Participants with radiologically confirmed disease relapse ≥ 6 months after their last platinum chemotherapy infusion in the previous line of treatment
• Participants who received 4-6 cycles of PBC during the induction phase of their current line of treatment.
• Participants assigned to bevacizumab must have received a minimum of 3 cycles of bevacizumab with 3 cycles of PBC prior to randomisation.
• Participants with non-progressive disease upon completion of PBC in their current line of treatment.
• Participants with documented BRCA mutation 1/2 must have received prior PARP inhibitor (unless ineligible due to contraindications, precautions, or intolerance).